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The last stages of assembly of the aminocou-
marin antibiotics, clorobiocin and coumermycin
A1, which target the GyrB subunits of bacterial
DNA gyrase, involve enzymatic transfer of the
pyrrolyl-2-carbonyl acyl group from a carrier
protein (CloN1/CouN1) to the 30-OH of the
noviosyl moiety of the antibiotic scaffold. The
enzyme, CouN7, will catalyze both the forward
and back reaction on both arms of the coumer-
mycin scaffold. This occurs via anO-acyl-Ser101-
CouN7 intermediate, as shown by transient la-
beling of the enzyme with [14C]acetyl-S-CouN1
as donor and by inactivating mutation of the ac-
tive site, Ser101, to Ala. The intermediacy of the
pyrrolyl-2-carbonyl-O-CouN7 allows net pyr-
role transfer between distinct aminocoumarin
scaffolds, for example, between the descarba-
moylnovobiocin scaffold and coumermycin A1
and vice versa. CouN7 also allows shuttling of
surrogate acyl groups between noviosyl-ami-
nocoumarin scaffolds to generate new antibi-
otic variants.
INTRODUCTION
The aminocoumarin antibiotics are natural products that
kill bacteria by blockade of topoisomerase II activity by
acting as competitive inhibitors of ATP hydrolysis in the
GyrB subunits of DNA gyrase [1–3], shutting down DNA
synthesis [4]. DNA gyrase is also the target of the synthetic
quinolone antibacterial agents, such as ciprofloxacin,
although they target the GyrA subunits [4, 5]. The three
most prevalent members of the aminocoumarin family,
all produced by streptomycetes, are novobiocin 1, cloro-
biocin 2, and coumermycin A1 3 (Figure 1). Novobiocin
and clorobiocin each have three parts: a prenyl-hydroxy-
benzoate in amide linkage to the aminocoumarin, in turn
glycosylated on a phenolic oxygen by an unusual L-
deoxyhexose, termed noviose. They differ at two places:
a methyl versus chlorine at position 8 of the coumarinChemistry & Biology 14, 6scaffold, and, more importantly, in the identity of the
acyl group on the 30-OH of the noviosyl ring. Novobiocin
has a carbamoyl group, while clorobiocin has a 5-methyl-
pyrrolyl-2-carbonyl acyl moiety. The X-ray structures of
novobiocin and clorobiocin bound to a 24 kDa ATPase
fragment of GyrB compared to ATP binding [6–8] show
not only that the antibiotics overlap the ATP binding site,
but also that the carbamoyl and pyrrolyl-2-carbonyl
groups are key pharmacophoric units interacting with
the GyrB active site. The third member of the aminocoum-
narin family is the pseudodimeric coumermycin with a
4-methyl-2,5-dicarboxypyrrole linker containing the
noviosyl-aminocoumarin in amide linkage to both carb-
oxyls of the linker [9]. The key acyl substituent at the 3-
position of each of the noviosyl units of coumermycin is,
as in clorobiocin, the 5-methylpyrrolyl-2-carbonyl unit.
Heide and his colleagues have carried out pioneering
work to sequence all three biosynthetic gene clusters
[10–12], perform genetic deletions to validate gene func-
tions [13–20], and have done in vivo manipulations and re-
placements to make a small set of hybrid aminocoumarins
and characterize them for antibiotic activity [13, 15, 21–27].
Notably, they identified seven ORFs, CloN1–7 and
CouN1–7, in the Clo and Cou clusters that are involved
in generating and transferring the 5-methylpyrrolyl-2-
carbonyl unit in the producer organisms. In complemen-
tary studies, we have shown that the activities of the
purified Clo/CouN3,4,5 are to activate L-proline (N4),
tether it as prolyl-N5, and then desaturate (N3) it to the
pyrrolyl-2-carbonyl thioester [28]. Most recently, we have
validated the in vivo-based experiments of Heide and
colleagues [20] that CouN1 is a free-standing peptidyl
carrier protein or thiolation domain and CouN7 is the
enzyme that shuttles the pyrrolyl-2-carbonyl or 5-methyl-
pyrrolyl-2-carbonyl to the desacyl form of clorobiocin/
novobiocin to create the pharmacophore for antibiotic
activity [29, 30] (M. Fridman, C.J.B., T. Lupoli, D. Kahne,
C.T.W., and S.G.-T., data not shown).
In this work, we have studied the mechanism of CouN7,
an a,b-hydrolase family member, and establish that it
generates a covalent acyl-O-Ser101 enzyme intermediate
during catalysis. The active site residue accepts the acyl
group from acyl-S-CouN1 donor and then delivers it
to the oxygen nucleophile of the desacylated noviosyl79–690, June 2007 ª2007 Elsevier Ltd All rights reserved 679
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CouN7-Mediated Acyl ShufflingFigure 1. Aminocoumarin Molecules Discussed in This Studyring of the aminocoumarin scaffold. In accord with this
mechanism, we show CouN7 will catalyze a net deacyla-
tion of coumermycin A1 3, removing either one or both of
the 5-methylpyrrolyl-2-carbonyl units in a net hydrolytic
reaction as the 5-methylpyrrolyl-O-CouN7 is intercepted
by water. In the presence of descarbamoylnovobiocin 4,
the acyl-O-CouN7 is instead captured by the cosubstrate,
leading to a net 5-methylpyrrolyl-2-carbonyl transfer. In
principle, this acyl group shuttle mechanism of CouN7
should enable regioselective acyl transfer to the des-
5-methylpyrrolylcoumermycin 5 scaffold to generate
antibiotic variants with one or two novel acyl group phar-
macophores. We demonstrate this by transfer of the
5-methylthiophene-2-carbonyl group from novobiocin to
the des-5-methylpyrrolylcoumermycin scaffold, generat-
ing mono- and bisacylated variants.
RESULTS
CouN7 Catalyzes Mono- and
Bis-5-Methylpyrrolyl-2-Carbonyl Transfer to the
Des-5-Methylpyrrolylcoumermycin Scaffold
CouN7 has been identified genetically as the last/next-to-
last enzyme in coumermycin A1 assembly, transferring the
pyrrolyl/5-methylpyrrolyl-2-carbonyl acyl moiety to the
noviosyl rings of both arms of the pseudodimeric antibiotic
scaffold [20]. Because of availability of the monomeric
descarbamoylnovobiocin 4 [31], in initial studies with
CouN7 purified after heterologous expression in Escheri-
chia coli, we tested the enzyme for regioselective acyl
transfer to the 30-OH of the noviosyl ring of descarbamoyl-
novobiocin to make pyrrolylnovobiocins [29]. The pre-680 Chemistry & Biology 14, 679–690, June 2007 ª2007 Elsevisumed in vivo substrate for CouN7, the des-5-methyl-
pyrrolylcoumermycin scaffold 5, is available from the
sequential action of three enzymes: CouL, CouM, and
CouP [32]. CouL does a double ligation of the aminocou-
marin nucleus to 2,5-dicarboxy-4-methylpyrrole to make
the bis amide on which CouM then transfers two noviosyl
groups from TDP-L-noviose. CouP makes the 40-O-methyl-
noviose on both arms of the maturing scaffold to yield 5
as putative acceptor substrate for CouN7.
With 5 as acceptor substrate and 5-methylpyrrolyl-2-
carbonyl-S-pantetheinyl CouN1 [29] as donor substrate,
the activity of CouN7 toward des-5-methylpyrrolyl-
coumermycin was assayed. As illustrated in Figure 2A,
CouN7 catalyzes a time-dependent utilization of 5 with
formation of two new compounds, as observed by
HPLC analysis. The initial peak (seen at 2 min incubation
time) has the mass spectrum of the mono-5-methylpyrro-
lylcoumermycin 6 (1003.3 [M + H]+ calculated, 1003.6
observed), while, at later times, the second peak that
grows in has the mass spectrum of 3 (1110.4 [M + H]+ cal-
culated, 1110.7 observed), and coelutes with authentic
coumermycin A1. Under the incubation conditions of
Figure 2A, about 90% of substrate 5 is converted equally
to the mono-5-methylpyrrolyl intermediate 6 and the
doubly acylated final antibiotic product 3 (Figure 2B).
Steady-state kinetic analysis (Figure 2C) shows a cata-
lytic rate constant (kcat) of 5.9 ± 0.2 min
1 and a Michaelis
constant (KM) for the acceptor substrate 5 of 2.9 ± 0.3 mM.
This kcat is about an order of magnitude faster than that of
0.73 min1, and the KM about 20-fold lower (60 mM) [29],
than that recently reported by us for transfer to the surro-
gate acceptor descarbamoylnovobiocin 4 [29], for aner Ltd All rights reserved
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CouN7-Mediated Acyl ShufflingFigure 2. CouN7 Generates Coumermycin A1 3 from 5-Methylpyrrolyl-S-CouN1 and Des-5-Methylpyrrolylcoumermycin 5
(A) HPLC time course of reaction containing 5.7 mM des-5-methylpyrrolylcoumermycin 5, 85.7 mM 5-methylpyrrolyl-S-CouN1, and 20 mM CouN7.
Products were monitored at 340 nm.
(B) Quantification of products from the reaction in (A). Triangles represent coumermycin A1 3, squares represent mono-5-methylpyrrolylcoumermycin
6, and diamonds represent des-5-methylpyrrolylcoumermycin 5.
(C) Michaelis-Menten kinetic parameters for utilization of des-5-methylpyrrolylcoumermycin 5 in the forward acylation reaction with 100 mM 5-methyl-
pyrrolyl-S-CouN1, 0.1 mM CouN7, and various concentrations of des-5-methylpyrrolylcoumermycin 5, ranging from 0.05 to 12 mM.improvement in catalytic efficiency of about 170-fold with
the native substrate of CouN7.
Catalysis Proceeds via an Acyl-Enzyme Intermediate
Involving Ser101
Bioinformatic analysis indicated that CouN7 is a member
of the a,b-hydrolase superfamily, with similarity to CmaE
in the coronamic acid biosynthetic pathway [33] and
SyrC in the syringomycin pathway [34]. We have recently
shown that CmaE [35] and SyrC [36] proceed via covalent
catalysis, as do many other members of this enzyme
superfamily. To evaluate this mechanistic possibility with
CouN7, we determined to use a radioactive surrogate
acyl donor, as labeled 5-methylpyrrolyl-2-carboxylate is
not readily available. To that end, commercially available
[14C]acetyl-CoA could be incubated with the apo form of
CouN1 and the purified phosphopantetheinyltransferase,
Sfp [37], with resultant [14C]acetyl-S-pantetheinyl transfer
to generate [14C]acetyl-S-CouN1. This served as the acyl
donor to CouN7 in brief incubations without an acyl
acceptor. The reactions were quenched with SDS and
rapidly analyzed by SDS-PAGE and autoradiography.
Figure 3A shows that the 10 kDa [14C]acetyl-S-CouN1 isChemistry & Biology 14, 6initially radioactive and, within 30 s, transfers [14C]acetyl
to CouN7. Labeled CouN7 is detectable for up to 15
min, after which radioactivity disappears. In parallel, the
radioactivity disappears from [14C]acetyl-S-CouN1. We
interpret these data to indicate that CouN7 autoacetylates
on an active site residue and, in the absence of acceptor
cosubstrate, will be captured by a water molecule for
net hydrolysis of the labile acetyl-enzyme species. En-
zyme reacetylation will occur through many cycles until
all [14C]acetyl-S-CouN1 donor molecules have undergone
net acetyl transfer to CouN7. Given a ratio of [14C]acetyl-
S-CouN1/CouN7 of 10:1 in this experiment, at least 10
enzyme acetylation/hydrolytic deacetylation events were
being monitored.
To validate that the observed transient labeling of
CouN7 by the [14C]acetyl group was the first half reaction
on a catalytic pathway, we turned to nonradioactive ace-
tyl-S-CouN1 as donor in the presence of acceptor sub-
strate 5. As shown in Figure 3B, CouN7 addition yields
two new HPLC-detectable products growing in over
time. The first peak has the mass spectrum of mono-
acetylcoumermycin 7 (938.3 [M + H]+ calculated, 938.6
observed), and the second peak has the mass spectrum79–690, June 2007 ª2007 Elsevier Ltd All rights reserved 681
Chemistry & Biology
CouN7-Mediated Acyl ShufflingFigure 3. Acylation of Des-5-Methylpyrrolylcoumermycin 5 Proceeds via an Acyl-O-CouN7 Intermediate by Using S101
(A) Time course of 250 mM [14C]acetyl-S-CouN1 reacting with 25 mM CouN7. Both an unlabeled coomassie-stained gel and a [14C] autoradiography
gel are shown.
(B) HPLC time course of reaction containing 171 mM acetyl-S-CouN1, 115 mM des-5-methylpyrrolylcoumermycin 5, and 20 mM CouN7. Products were
monitored at 340 nm.
(C) Same as (A), but with the CouN7 S101A mutant. Ladder
1 is Bio-Rad prestained SDS-PAGE standard, broad range. Ladder* is [14C]methylated
proteins, GE Healthcare.of the bisacetyl variant of coumermycin 8 (980.3 [M + H]+
calculated, 980.5 observed). Therefore, we conclude that
the net acetyl transfer to the des-5-methylpyrrolylcoumer-
mycin scaffold is a two-step process and goes via an
acetyl-CouN7 covalent enzyme intermediate. Furthermore,
CouN7 can catalyze acetyl transfer to both arms of the des-
5-methylpyrrolylcoumermycin scaffold, previewing other
possible acyl transfers.
Homology with CmaE and SyrC suggests that CouN7
uses the side chain OH of Ser101 as catalytic nucleo-
phile, even though CmaE and SyrC use the thiolate side
chain of active site Cys residues as nucleophiles [35,
36]. This difference could be attributed to the eventual nu-
cleophilic acceptor of the acyl moiety being transferred.
Whereas CmaE and SyrC catalyze net transthioesterifica-
tion, CouN7 catalyzes formation of an oxoester from
a thioester. The S101A mutant of CouN7 was constructed,
expressed, and purified, and when subjected to activity
analysis, was catalytically inactive. In particular, when
the [14C]acetyl transfer experiment of Figure 3A was
repeated with the S101A mutant enzyme, as shown in
Figure 3C, there was no transient acetylation of the
CouN7 mutant enzyme, nor was there any loss of radio-
activity from [14C]acetyl-S-CouN1. We conclude that
Ser101 is indeed part of the CouN7 catalytic apparatus682 Chemistry & Biology 14, 679–690, June 2007 ª2007 Elsevieand the likely nucleophile for covalent acyl-enzyme forma-
tion in each catalytic turnover. The shuttling of the 5-methyl-
pyrrolyl-2-carbonyl acyl group from thiol donor to alcohol
acceptor (30-OH of noviosyl ring) goes through an enzyme
oxoester species.
CouN7 Catalyzes the Back Reaction:
Deacylation of Coumermycin A1
The intermediacy of a covalent acyl-O-enzyme intermedi-
ate, and the observation that the acetyl-enzyme version
was hydrolytically decomposed in the absence of the sec-
ond substrate, raised the question of whether the normal
5-methylpyrrolyl-2-carbonyl acyl-enzyme might be hydro-
lytically labile. In turn, given that both the covalent enzyme
intermediate and the coumermycin product was a pyr-
rolyl-2-carboxy ester, we asked if CouN7 would catalyze
the reverse acyl transfer as manifested in hydrolysis of
coumermycin A1. Indeed, the data of Figure 4A show
HPLC traces that indicate CouN7-mediated conversion
of the bis-5-methylpyrrolylcoumermycin A1 antibiotic 3
first to the monodes-5-methylpyrrolyl 6 and then to the
bisdes-5-methylpyrrolyl scaffold 5. The hydrolytic deacy-
lation follows Michaelis-Menten kinetics, yielding a kcat of
0.054 ± 0.002 min1 and a KM of 63 ± 9 mM for coumermy-
cin in the back reaction (Figure 4B). A separate set ofr Ltd All rights reserved
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CouN7-Mediated Acyl ShufflingFigure 4. CouN7Will Deacylate Coumer-
mycin A1
(A) HPLC time course of reaction containing
50 mM coumermycin A1 3, and 20 mM CouN7.
Products were monitored at 340 nm.
(B) Michaelis-Menten kinetic parameters for
coumermycin A1 3 in the reverse deacylation
reaction with 3, 7, or 15 mM CouN7, and various
concentrations of coumermycin A1 3 ranging
from 5 to 500 mM.experiments showed that CouN7 will not deacylate novo-
biocin 1 (data not shown), suggesting the carbamoyl
group is not an acceptable acyl surrogate for CouN7.
In order to verify that the reverse deacylation proceeds
via the same Ser101-O-acyl-enzyme intermediate, and
was not attributed to a potential secondary editing site
on CouN7, we turned again to radioactive labeling exper-
iments. With [14C]acetyl-CoA loaded onto CouN1 by the
action of Sfp, a small scale-up reaction was performed
to generate mono- and bisacetylated versions of coumer-
mycin, formed by the action of CouN7 on the des-5-
methylpyrrolylcoumermycin scaffold 5. These [14C]-labeled
coumermycins were then incubated with CouN7 for vari-
ous amounts of time, quenched with SDS, and rapidlyChemistry & Biology 14,analyzed by SDS-PAGE and autoradiography. As illus-
trated in Figure 5, the [14C]acetyl radiolabel is transferred
from coumermycin to CouN7 within 30 s. Labeled
CouN7 is detectable throughout the 120 min time course,
although in lesser amounts as time progresses. In parallel
experiments with the CouN7 S101A mutant, no radioactive
label is transferred from acetylated coumermycin. Thus,
CouN7 deacylates coumermycin via its Ser101 active-site
residue. The acyl-enzyme species can then reacetylate
the coumermycin scaffold or can be captured by a water
molecule for net hydrolysis of the labile acetyl-enzyme
species.
Two points can be drawn. First, CouN7 will catalyze
reversible transfer of the 5-methylpyrrolyl-2-carbonyl679–690, June 2007 ª2007 Elsevier Ltd All rights reserved 683
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CouN7-Mediated Acyl ShufflingFigure 5. Deacylation of Coumermycin
A1 3 Proceeds via the Same Ser101 acyl-
O-CouN7 Intermediate as the Forward
Acylation Reaction
Time course of 50 mM [14C]acetylcoumermycin
7/8 reacting with 25 mM CouN7 or CouN7
S101A. Both an unlabeled coomassie-stained
gel and [14C] autoradiography gel are shown.
Ladder1 is Bio-Rad prestained SDS-PAGE
standard, broad range. Ladder* is [14C]methyl-
ated proteins, GE Healthcare.acyl group and the 5-methylpyrrolyl-2-carbonyl enzyme
intermediate then is susceptible to hydrolysis. Second,
the kcat for the back reaction is about 1% the kcat for the
forward reaction. It is not yet clear what steps are rate
determining in either direction, but at a ratio of 1:100 for
coumermycin acylation to net deacylation, the hydrolysis
of the acyl-O-CouN7 enzyme intermediate should not
preclude accumulation of the final antibiotic at the end
of the multistep biosynthetic pathway. However, as noted
below, the catalytic capacity of CouN7 for the back acyl
transfer suggested that additional shuttling reactions
could be investigated.
Shuttling of the 5-Methylpyrrolyl-2-Carbonyl Group
between Coumermycin and Novobiocin Scaffolds
The hydrolytic back reaction for CouN7-mediated 5-
methylpyrrolyl-2-carbonyl transfer from coumermycin A1
to water suggested that one might be able to intercept
the proposed 5-methylpyrrolyl-2-carbonyl-enzyme inter-
mediate with an alternate noviose-containing acceptor.
Descarbamoylnovobiocin was readily available and,
when incubated with coumermycin A1 and enzyme, acyl
transfer was demonstrable as shown in Figure 6. During
the 50 min incubation, almost all the starting coumermycin
A1 3 is gone after 22 min. As anticipated, the monodeacy-
lated coumermycin scaffold 6 builds up, followed by the
bisdesacyl 5. Meanwhile, a small 5-methylpyrrolylnovo-
biocin 9 peak is detectable even at 0.5 min, and grows
in over the first 30 min of incubation. Under these reaction
conditions, 62% ± 1% of the 5-methylpyrrole-2-carbonyl
removed from coumermycin A1 is successfully transferred
to descarbamoylnovobiocin by CouN7, the rest presum-
ably being lost to hydrolysis by water. Because CouN7
has a higher affinity for the coumermycin scaffold com-
pared to the novobiocin scaffold, these kinds of incubations
were run with large molar excess of the descarbamoylno-
vobiocin scaffold 4. Otherwise, it does not outcompete
reacylation of monodesacyl 6 and bisdesacyl 5.
Transfer of an Alternate Acyl Group between
the Novobiocin and Coumermycin Scaffolds:
5-Methylthiophene-2-Carbonyl Transfer
As a test for CouN7-dependent transfer of an alternate
acyl group between noviosyl acceptors, 5-methylthio-684 Chemistry & Biology 14, 679–690, June 2007 ª2007 Elseviephene-2-carbonyl was utilized as a pyrrole-2-carbonyl
substitute. We have recently demonstrated that Sfp will
utilize the 5-methylthiophene-CoA with apo CouN1 to
generate the sulfur-substituted, five-membered hetero-
cyclic acyl donor (M. Fridman, C.J.B., T. Lupoli, D. Kahne,
C.T.W., and S.G.-T., data not shown). That molecule could
be used for direct transfer by CouN7, either to descarba-
moylnovobiocin 4 to yield 10, or to the des-5-methylpyrro-
lylcoumermycin scaffold 5 to yield 11 and 12 (Figure 7A,
standards). When 10was incubated with 5 in the presence
of enzyme, the HPLC traces of Figure 7A show transfer of
the 5-methylthiophene-2-carbonyl group into the coumer-
mycin scaffold. The monoacylated coumermycin scaffold
11 is precursor to a small amount of bisacyl coumermycin
product 12. Under these reaction conditions, 80% ± 5%
of the 5-methylthiophene-2-carbonyl removed from 5-
methylthiophene novobiocin is successfully transferred
to des-5-methylpyrrolylcoumermycin by CouN7, the rest
presumably being lost to hydrolysis by water. With optimi-
zation of substrates, enzyme concentration, and time, it
should be possible to make amounts of mono- and bisacyl
coumermycin derivatives, including ones with two distinct
acyl groups on each noviosyl arm, for evaluation of any
improved antibiotic properties.
DISCUSSION
In recognition of the continuing need for new antibiotics to
combat contemporary drug-resistant bacterial patho-
gens, several research groups have turned back to natural
product scaffolds. These include both new molecules,
such as platensimycin [38], and previously discovered
classes, including the lipodepsipeptides, such as dapto-
mycin [39, 40], ADEPs [41], and mannopeptimycins [42],
for reevaluation of clinical utility. We [28, 29, 31, 32, 43–
48] and the group of Lutz Heide and colleagues at Tu¨bingen
[10–27, 31, 32, 49–52] have been studying the biosynthe-
sis of the aminocoumarin class of antibiotics that target
the type II topoisomerase DNA gyrase [1–3]. This enzyme
is a validated killing target for bacteria, as exemplified by
the widespread use of several synthetic quinolone anti-
bacterial drugs [4, 5]. The quinolones act on the GyrA sub-
units, while the aminocoumarins, which have not been in
wide clinical use, target the GyrB subunits—specifically,r Ltd All rights reserved
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CouN7-Mediated Acyl ShufflingFigure 6. CouN7 Will Shuttle 5-Methyl-
pyrrolyl-2-Carbonyl from Coumermycin
A1 3 to Descarbamoylnovobiocin 4
(A) HPLC time course of reactions containing
50 mM coumermycin A1 3, 200 mM descarba-
moylnovobiocin 4, and 10 mM CouN7. Stan-
dard 1 is of descarbamoylnovobiocin 4 and
5-methylpyrrolylnovobiocin 9. Standard 2 is
of des-5-methylpyrrolylcoumermycin 5. Stan-
dard 3 is of mono-5-methylpyrrolylcoumermy-
cin 6 and bis-5-methylpyrrolylcoumermycin 3
generated from des-5-methylpyrrolylcoumer-
mycin 5. Products were monitored at 340 nm.
(B) Scheme depicting the reaction in (A).the ATPase site involved in driving DNA coiling [1–3]. X-ray
structures of the N-terminal 24 kDa fragment of GyrB
complexed with either novobiocin or clorobiocin reveal
that the acyl substituent on the 30-OH of the noviosyl
ring projects into the GyrB ATPase active site as the key
pharmacophore [6–8]. The replacement of the carbamoyl
moiety in novobiocin by the 5-methylpyrrolyl-2-carbonyl
substituent in clorobiocin (and coumermycin) results in
a 10-fold increase in affinity [30]. The noviosyl-aminocou-
marin framework can be viewed as a platform for presen-
tation of the 30-O-acyl groups to GyrB.
We and the Heide group have thus been focusing on the
biosynthesis and the regioselective installation of the 5-
methylpyrrolyl-2-carbonyl moiety in the last stages of
aminocoumarin antibiotic maturation [20, 29]. Building
on the in vivo evidence of Heide and colleagues, we
have recently demonstrated that CouN1 is the free-stand-
ing carrier protein domain that, when acylated on the
phosphopantetheinyl prosthetic arm, is the acyl donor,
and that CouN7 is the 5-methylpyrrolyl-2-carbonyl acyl-
transferase.
In this study, we have noted that CouN7 can catalyze a
slow deacylation of coumermycin A1, resulting in a net
transfer of the 5-methylpyrrolyl-2-carbonyl unit to water to
yield the free 5-methylpyrrolylcarboxylate and first mono-
5-methylpyrrolylcoumermycin 6, and subsequently des-
5-methylpyrrolylcoumermycin 5. The kcat of 0.054 min
1
is about one one-hundredth the rate of the forward reac-
tion, 5.9 min1, such that the hydrolytic deacylation reac-Chemistry & Biology 14, 6tion is not a concern in the buildup of the mature coumer-
mycin. Nonetheless, we felt that the hydrolytic back
reaction capability of CouN7 might be mechanistically
diagnostic of an acyl-enzyme intermediate.
Direct demonstration of an acylated CouN7 was ob-
tained with [14C]acetyl-S-pantetheinyl CouN1 as surro-
gate acyl donor. This derived from commercially available
[14C]acetyl-CoA, the apo form of the CouN1 carrier pro-
teins, and the phosphopantetheinyltransferase Sfp [37],
which we have previously used to install 5-methylpyr-
rolyl-2-carbonyl- and pyrrolyl-2-carbonyl-S-pantetheinyl
units on CouN1 [29]. There is clear evidence from SDS-
PAGE analysis that a [14C]acetyl-CouN7 forms transiently
and then transfers the acetyl group to the des-5-methyl-
pyrrolylcoumermycin scaffold to yield first the monoace-
tylcoumermycin 7, and then the bisacetylcoumermycin 8
variants. Thus, the acetyl-CouN7 form of the enzyme is
chemically competent as a reaction intermediate. Bioin-
formatic analysis with other a,b-hydrolases suggests the
side chain OH of Ser101 as candidate for catalytic nucle-
ophile. The S101A mutant was indeed catalytically inactive
and could not be acetylated. Consistent with the mecha-
nistic prediction, we thus identify the acyl-enzyme in
normal turnover as the 5-methylpyrrolyl-2-carbonyl-O-
Ser101-CouN7.
The fact that CouN7 catalysis proceeds via covalent
acyl-enzyme formation suggested that it might be
possible to transfer the itinerant acyl group between
different noviosyl-aminocoumarin scaffolds. This was first79–690, June 2007 ª2007 Elsevier Ltd All rights reserved 685
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CouN7-Mediated Acyl ShufflingFigure 7. CouN7 Will Shuttle 5-
Methylthiophene-Carbonyl from 5-Meth-
ylthiophene-Novobiocin 10 to Des-5-
Methylpyrrolylcoumermycin 5 and
Mono-5-Methylthiophene-Coumermycin
11
(A) HPLC time course of reactions containing
50 mM 5-methylthiophene-novobiocin 10,
120 mM des-5-methylpyrrolylcoumermycin
5, and 20 mM CouN7. Standard 1 is of descar-
bamoylnovobiocin 4. Standard 2 is of mono-5-
methylthiophene-coumermycin 11 and bis-5-
methylthiophene-coumermycin 12 generated
from des-5-methylpyrrolylcoumermycin 5.
Products were monitored at 340 nm.
(B) Scheme depicting the reaction in (A).validated by starting with coumermycin A1 3 and descar-
bamoylnovobiocin 4 (free noviosyl 30-OH) as the potential
acceptor. Addition of CouN7 led to a time-dependent de-
acylation of coumermycin A1 and concomitant formation
of the 5-methylpyrrolylnovobiocin 9 product, reflecting
a successful competition by the novobiocin scaffold for
the 5-methylpyrrolyl-O-Ser101-CouN7.
In terms of potential utility for creating coumermycin
(and clorobiocin) analogs with altered 30-O-acyl pharma-
cophores and consequent distinctions in antibiotic prop-
erties, transfer of other acyl groups between scaffolds
would be of interest. We have recently investigated
CouN7 for permissivity for acyl group transfer by starting
from several heterocyclic-2-carboxylates, conversion to
the acyl-CoAs, installation as acyl-S-pantetheinyl-CouN1
derivatives, and then transfer to the descarbamoylnovo-
biocin scaffold (M. Fridman, C.J.B., T. Lupoli, D. Kahne,
C.T.W., and S.G.-T., data not shown). The 5-methylthio-
phene-2-carboxylate in which the nitrogen of the pyrrole
ring has been replaced by sulfur is a prototypically good
substrate, allowing accumulation of the 5-methylthio-
phenyl derivative of novobiocin. Staring from this variant,
5-methylthiophene-novobiocin 10, and the des-5-methyl-
pyrrolylcoumermycin 5, CouN7 transfers the 5-methyl-
thiophene-2-carbonyl sequentially to the 30-OH of the
noviosyl arms in the coumermycin scaffold. It is likely
that bisacyl coumermycins, including those with different
acyl moieties on each of the novioses in the two arms of686 Chemistry & Biology 14, 679–690, June 2007 ª2007 Elseviercoumermycin, can be constructed by such enzymatic
shuffling of acyl groups from acyl-CoAs via the CouN1
carrier protein route.
Our findings demonstrating shuffling of acyl moieties
between distinct aminocoumarin scaffolds by the acyl-
transferase CouN7 parallel those recently reported for
glycosyltransferases in the vancomycin and calicheamicin
biosynthetic systems [53]. In that study, it was shown that
glycosyltransferases too are reversible, and can deglyco-
sylate their products to form NDP sugars, which in turn
can be transferred to new scaffolds. The reversibility of
tailoring enzymes within natural product biosynthetic sys-
tems may be a general phenomenon, and could possibly
be exploited for the combinatorial synthesis of novel
compounds.
CouN7 and its close congener, CloN7, in clorobiocin as-
sembly join two other tailoring enzymes recently identified
in NRPS assembly lines. CmaE shuttles an allo-Ile group
between carrier protein domains in coronamic acid bio-
genesis [33], while SyrC moves a 4-chloro-Thr between
pantetheinyl arms of SyrB1 and SyrE in maturation of the
phytotoxin syringomycin [36]. While CmaE and SyrC use
active-site Cys thiolate side chains as nucleophiles to
make aminoacyl-S-enzyme intermediates in the net trans-
thiolations, CouN7 uses an acyl-O-Ser enzyme intermedi-
ate and transfers the migrating acyl moiety to an oxygen
nucleophile in the coumermycin scaffold. It will be of inter-
est to ascertain other assembly lines with shuttle enzymesLtd All rights reserved
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assembly lines in natural product biosynthetic diversifica-
tion efforts.
SIGNIFICANCE
Bacterial DNA gyrase is targeted by the synthetic qui-
nolone antibacterial agents on the GyrA subunits and
the natural product aminocoumarins on the GyrB sub-
units in the ATP binding site. The bicyclic amino-
coumarin scaffolds of clorobiocin and coumermycin
present an L-noviosyl sugar substituted at the 30-OH
with a 5-methylpyrrolyl-2-carbonyl acyl moiety as the
pharmacophore. This acyl group is installed at the
end of the biosynthetic pathway by the acyltrans-
ferases, CloN7/CouN7. Here, we show that CouN7 cat-
alyzes a slow hydrolytic deacylation of the 30-O-acyl
groups on both arms of coumermycin via an acyl-O-
Ser101-CouN7 intermediate. The acyl-O-CouN7 enzyme
intermediate can be intercepted by descarbamoylno-
vobiocin 4 to shuttle the 5-methylpyrrolyl-2-carbonyl
group between coumarin scaffolds. Also, use of an
alternate acyl group, such as the 5-methylthiophene-
2-carbonyl moiety presented on the pantetheinyl arm
of the CouN1 donor protein or on the 30-OH of L-nov-
iose on the novobiocin scaffold, allows CouN7-medi-
ated mono- and bis-acylation of the des-5-methylpyr-
rolylcoumermycin scaffold 5. Thus, CouN7 should
be useful for shuttling different acyl groups between
the noviosyl-30-OH units of different aminocoumarins
to generate variant pharmacophores in this natural
product antibiotic class.
EXPERIMENTAL PROCEDURES
Materials and General Methods
Standard recombinant DNA, molecular cloning, and microbiological
procedures were performed as previously described [54]. Competent
TOP10 and BL21 (DE3)E. coli strains were from Invitrogen. Oligonucle-
otide primers were from Integrated DNA Technologies. Phusion DNA
polymerase, restriction enzymes, and T4 DNA ligase were from New
England Biolabs. Plasmid pET28a was from Novagen. DNA sequenc-
ing to verify PCR fidelity was performed on double-stranded DNA by
the Molecular Biology Core Facilities of the Dana Farber Cancer Insti-
tute (Boston, MA). Plasmid DNA preparation was performed with the
Qiaprep kit from Qiagen. Gel extraction of DNA fragments, as well as
restriction endonuclease cleanup, were done with the GFX kit from
GE Healthcare. Ni-NTA Superflow resin was from Qiagen. SDS-
PAGE gels were from Invitrogen. Protein samples were concentrated
with a 10KMWCO Amicon Ultra device from Millipore, and final protein
concentrations were calculated with the protein’s absorbance at 280
nm and the predicted molar extinction coefficient.
Radio-HPLC was performed on a Beckman Coulter System Gold
instrument equipped with a b-Ram module 3 radioisotope detector
(IN/US Systems). LCMS identification was carried out on a Shimadzu
LCMS-QP8000a equipped with two LC-10ADVP liquid chromato-
graphy pump modules, an SPD-10AVVP UV-vis detector, an SIL-
10ADVP autosampler module, and a Vydac C18 Mass Spec column
(5 mm, 2.13 250 mm). Analytical HPLC was performed with a Beckman
Coulter System Gold instrument. Radiolabeled SDS-PAGE gels were
exposed to a BAS-IIIs image plate for approximately 24 hr and subse-
quently read by a Typhoon 9400 variable mode imager (GE Healthcare)
followed by analysis with ImageQuant Software.Chemistry & Biology 14, 6[14C]acetyl-CoA (56 mCi/mmol) was purchased from GE Healthcare.
5-Methylpyrrolyl-2-carbonyl-CoA [29], 5-methylthiophene-2-carbonyl-
CoA and descarbamoylnovobiocin (M. Fridman, C.J.B., T. Lupoli, D.
Kahne, C.T.W., and S.G.-T., data not shown), and des-5-methylpyrro-
lylcoumermycin (CouLM product + CouP) [32] were obtained as previ-
ously descibed. Coumermycin A1 was purchased from Sigma and
novobiocin was purchased from Calbiochem.
Cloning and CouN7 S101A
CouN7 S101A was obtained by the splicing by overlap extension
method [55] with pCouN7-pET28a [29] as template. The template
was amplified with the following primers in the first round (underlined,
restriction site; italics, mutation): (a) 50-GCATGACTCATATGGCGAAC
CACCGACCGG-30 and 50-CAGCGCGAGCGCGGTCACACCGCCTCC
CGCGCTGGCGAAC-30; (b) 50-GCCGGGCCGGCGTACTTGTTCGCC
AGCGCGGGAGGCGGTG-30 and 50-CGTGAATTCTTAGGGACCGTT
GTGCGAGCGC-30. The a and b fragments were mixed and then
amplified with the first forward primer from the a fragment and the
second reverse primer from the b fragment. The final PCR product
was digested with NdeI/HindIII and ligated into a similarly digested
pET28a vector.
Protein Expression
CouN1, CouN7 wild-type, and CouN7 S101A mutant proteins were
expressed and purified as described previously [29]. The mutant
protein expressed at 20 mg/l and behaved identically to the wild-type
during isolation.
Characterization of CouN7 Activity on
Des-5-Methylpyrrolylcoumermycin 5
The initial reaction time course to determine the ability of CouN7 to
acylate des-5-methylpyrrolylcoumermycin was performed as follows.
The CouN1 loading reaction (50 ml) contained 10 mM MgCl2, 75 mM
Tris (pH 7.5), 1 mM TCEP (pH 7), 150 mM CouN1, 150 mM 5-methyl-
pyrrolyl-CoA, and 5 mM Sfp, and proceeded for 1 hr at RT. The reaction
to produce des-5-methylpyrrolylcoumermycin (25 ml) contained 10%
DMSO, 75 mM Tris (pH 7.5), 10 mM MgCl2, 20 mM CouLM product,
500 mM SAM, 1 mg/ml BSA, and 10 mM CouP, and proceeded for
6 hr at RT. The two reactions were then mixed, initiated with 12.5 ml
of 149 mM CouN7, and quenched with 150 ml of methanol at desired
time points. The quenched reaction was placed at 20C for 20 min,
centrifuged at 13,000 rpm to pellet protein, and the supernatant was
added to 50 ml of 1 M ammonium acetate (pH 3.5). HPLC analysis
was performed on a Vydac C18 small-pore column (250 3 4.6 mm)
with a gradient of 15%–100% acetonitrile over 30 min, starting with
0.1% TFA in H2O. Products were monitored at 340 nm.
Kinetics were performed as follows. A 40 mM solution of des-5-meth-
ylpyrrolylcoumermycin was made by incubating 10% DMSO, 75 mM
Tris (pH 7.5), 10 mM MgCl2, 40 mM CouLM product, 500 mM SAM,
1 mg/ml BSA, and 25 mM CouP for 3 hr at RT. Reactions for priming
CouN1 contained 10 mM MgCl2, 75 mM Tris (pH 7.5), 1 mM TCEP
(pH 7), 150 mM CouN1, 150 mM 5-methylpyrrolyl-CoA, and 5 mM Sfp,
and proceeded for 1 hr at RT. The final 75 ml reaction contained 50 ml
of the CouN1 priming reaction, 0.1 mM CouN7, and various concentra-
tions of des-5-methylpyrrolylcoumermycin (0.05, 0.1, 0.3, 0.75, 2, 5,
and 12.5 mM). Reactions were quenched and analyzed as described
previously here.
Reactions to visualize the acyl-enzyme intermediate were done at
RT and contained 75 mM Tris (pH 7.5), 10 mM MgCl2, 250 mM
CouN1, 5 mM Sfp, 375 mM unlabeled acetyl-CoA, 125 mM [14C]ace-
tyl-CoA, and, after 1 hr to allow for CouN1 loading, 25 mM of
CouN7(S101A) was added. At various time points, 5 ml of sample was
quenched into 10 ml of 23 SDS sample buffer (125 mM Tris [pH 6.8],
41% SDS, 20% glycerol, 0.01% Brilliant Blue) and loaded onto
a 12% NuPAGE Bis-Tris gel. After running, the gel was transferred to
a PVDF membrane (Bio-Rad) before phosphorimaging.
Reactions to produce acetylated coumermycin contained the fol-
lowing. A 345 mM solution of des-5-methylpyrrolylcoumermycin was79–690, June 2007 ª2007 Elsevier Ltd All rights reserved 687
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345 mM CouLM product, 5 mM SAM, 1 mg/ml BSA, and 50 mM CouP
for 3 hr at RT. Reactions for priming CouN1 contained 10 mM MgCl2,
75 mM Tris (pH 7.5), 1 mM TCEP (pH 7), 300 mM CouN1, 400 mM acetyl-
CoA, and 10 mM Sfp, and proceeded for 1 hr at RT. The final 50 ml acet-
ylation reaction contained 28.52 ml of the CouN1 priming reaction,
16.67 ml of the 345 mM des-5-methylpyrrolylcoumermycin, 20 mM
CouN7, and 10% DMSO. A 4 ml aliquot of the reaction was quenched
into 150 ml methanol, 71 ml of water was added, and analysis was con-
ducted by HPLC as described previously here.
Characterization of CouN7-Mediated Deacylation
of Coumermycin A1
Kinetics of deacylation were carried out as follows. Reactions con-
tained 75 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM TCEP (pH 7), 1 mg/
ml BSA, either 3, 7, or 15 mM CouN7, and various amounts of coumer-
mycin A1, ranging between 5 and 500 mM. At desired time points, 75 ml
reactions were quenched and analyzed as described previously here.
To produce [14C] labeled mono- and bisacetylcoumermycin, a small
scale up was performed. A 345 mM solution of des-5-methylpyrrolyl-
coumermycin was made by incubating 10% DMSO, 75 mM Tris
(pH 7.5), 10 mM MgCl2, 345 mM CouLM product, 5 mM SAM, 1 mg/ml
BSA, and 50 mM CouP for 3 hr at RT. Reactions for priming CouN1 con-
tained 10 mM MgCl2, 75 mM Tris (pH 7.5), 1 mM TCEP (pH 7), 300 mM
CouN1, 233 mM [14C]acetyl-CoA, 250 mM unlabeled acetyl-CoA, and
10 mM Sfp, and proceeded for 1 hr at RT. The final 200 ml reaction
contained 10% DMSO, 115 mM of des-5-methylpyrrolylcoumermycin,
114 ml of the CouN1 priming reaction, and 20 mM CouN7. After 20 min,
the reaction was quenched into 400 ml methanol and worked up as
usual. The mono- and bisacetylated products were purified by
HPLC, evaporated to dryness, and redissolved in DMSO for future use.
Reactions to visualize the acyl-enzyme intermediate contained
75 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM TCEP (pH 7), 25 mM
CouN7(S101A), 50 mM [
14C]acetylcoumermycin 7/8, and 10% DMSO.
At various time points, 5 ml of sample was quenched into 10 ml of 23
SDS sample buffer (125 mM Tris [pH 6.8], 41% SDS, 20% glycerol,
0.01% Brilliant Blue) and loaded onto a 12% NuPAGE Bis-Tris gel.
After running, the gel was transferred to a PVDF membrane (Bio-Rad)
before phosphorimaging.
Shuttling of Acyl Substituents between Scaffolds
Reactions to demonstrate shuttling of 5-methylpyrrole between cou-
mermycin A1 and descarbamoylnovobiocin 4 contained 75 mM Tris
(pH 7.5), 10 mM MgCl2, 1 mM TCEP (pH 7), 1 mg/ml BSA, 200 mM des-
carbamoylnovobiocin, 3 mM coumermycin A1, 7.5% DMSO, and 10 mM
CouN7. At desired time points, the reactions were quenched and
analyzed by HPLC as described previously here, except that a
Phenomenex 5 m C18 Luna (250 3 4.6 mm) column was used instead.
Standards for 5-methylpyrrolylnovobiocin 9 and mono-5-methylpyrro-
lylcoumermycin 6 began by priming N1 with 5-methylpyrrolyl-CoA.
Reactions contained 75 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM TCEP
(pH 7), 500 mM 5-methylpyrrolyl-CoA, 400 mM CouN1, and 10 mM Sfp,
and proceeded for 1 hr at RT. Final acylation reactions contained 50 ml
of the N1 priming reaction, 10% or 5% DMSO, 10 mM des-5-methyl-
pyrrolylcoumermycin or 200 mM descarbamoylnovobiocin, 1 mg/ml
BSA, and 3 or 25 mM CouN7, respectively. The coumermycin reaction
was quenched at 15 min, and the novobiocin reaction was quenched
at 2 hr.
The scale-up reaction for producing 5-methylthiophene-novobiocin
10 contained 10 mM MgCl2, 75 mM Tris (pH 7.5), 1 mM TCEP (pH 7),
2.5 mM 5-methylthiophene-CoA, 1.5 mM CouN1, and 20 mM Sfp
(150 ml). After priming for 1 hr at RT, 5% DMSO, 125 mM descarbamoyl-
novobiocin, 1 mg/ml BSA, and 125 mM CouN7 was added to a final
volume of 225 ml, and the reaction was quenched after 2 hr as
described previously here. The product was purified by HPLC, evapo-
rated to dryness, and redissolved in DMSO for future use.
Reactions to demonstrate shuttling of 5-methylthiophene between
novobiocin and des-5-methylpyrrolylcoumermycin contained 75 mM688 Chemistry & Biology 14, 679–690, June 2007 ª2007 ElsevTris (pH 7.5), 10 mM MgCl2, 1 mM TCEP (pH 7), 1 mg/ml BSA, 50 mM
5-methylthiophene-novobiocin, 120 mM des-5-methylpyrrolylcoumer-
mycin, and 20 mM CouN7. At desired time points, the reactions were
quenched and analyzed by HPLC as described previously here. Stan-
dards for mono- and bis-5-methylthiophene-coumermycin began by
priming N1 with 5-methylpyrrolyl-CoA. Reactions contained 75 mM
Tris (pH 7.5), 10 mM MgCl2, 1 mM TCEP (pH 7), 400 mM 5-methylthio-
phene-CoA, 300 mM CouN1, 10 mM Sfp, and proceeded for 1 hr at RT.
Final acylation reactions contained 6.84 ml of the N1 priming reaction,
10% DMSO, 115 mM des-5-methylpyrrolylcoumermycin, and 20 mM
CouN7. The reaction was quenched at 15 min.
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